John W. Newcomer, MD
Original Research
Brexpiprazole in Patients With MDD and Prediabetes
August 28, 2023
Some atypical antipsychotics, while efficacious as adjunctive treatments in major depressive disorder (MDD), can lead to adverse effects and weight gain. Adjunctive brexpiprazole had a limited impact on metabolic...
Original Research
Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis
September 21, 2021
Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
Original Research
Brexpiprazole in MDD—Metabolic Parameters and Weight
October 1, 2019
Adjunctive atypical antipsychotics can increase antidepressant response in depressed patients, but may cause adverse metabolic effects. This study examines the metabolic effects of adjunctive brexpiprazole in patients with major...
